Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
about
Flesh quality loss in response to dietary isoleucine deficiency and excess in fish: a link to impaired Nrf2-dependent antioxidant defense in muscleEffects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cellsSynergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.Regulation of epidermal growth factor receptor signaling and erlotinib sensitivity in head and neck cancer cells by miR-7CK2 in Cancer: Cellular and Biochemical Mechanisms and Potential Therapeutic Target.Phosphoproteomics Identifies CK2 as a Negative Regulator of Beige Adipocyte Thermogenesis and Energy Expenditure.Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivityPhosphorylation of apoptosis repressor with caspase recruitment domain by protein kinase CK2 contributes to chemotherapy resistance by inhibiting doxorubicin induced apoptosis.Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer.Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs.Polymer nanoparticulate drug delivery and combination cancer therapy.Casein kinase: the triple meaning of a misnomer.Protein kinase CK2 in breast cancer: the CK2β regulatory subunit takes center stage in epithelial plasticity.Casein kinases as potential therapeutic targets.Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.Protein kinase CK2 is widely expressed in follicular, Burkitt and diffuse large B-cell lymphomas and propels malignant B-cell growth.Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.Cell surface area and membrane folding in glioblastoma cell lines differing in PTEN and p53 status.2-alkyl(aryl)-quinazolin-4(3H)-thiones, 2-R-(quinazolin-4(3H)-ylthio)carboxylic acids and amides: synthesis, molecular docking, antimicrobial and anticancer properties.Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.A chemical-genetic interaction map of small molecules using high-throughput imaging in cancer cells.Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme.Mig-6 deficiency cooperates with oncogenic Kras to promote mouse lung tumorigenesis.Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.[The targets research of non-small cell lung cancer targeted therapy].
P2860
Q28384286-DF1CA484-8D0B-4872-ACC9-B871061F218CQ28485087-F25CFCC6-06FF-455C-A794-4D8992F0F258Q34265716-6B429FE2-9D43-4F1E-9026-CF36C7829A8FQ34463471-8A2EB45D-A429-46B7-BB72-DC97431860A7Q36263671-459EADE5-ECE8-4E93-8C9B-CBA7EA157EDFQ36348851-461185EC-2ABB-438F-9579-3E7758DA7CD5Q36382520-3CCF8A08-306C-4235-90EF-5BBE52819201Q36413878-42C03836-DE8D-4D60-90F6-B404896C3EE3Q37698720-506E6227-0B90-4960-BA6E-1EEDAB0DCD75Q38045433-7BE5E399-B034-464B-A16E-E93E80DBE033Q38059506-8B5EBD13-E66F-4043-95EE-AF6B696C8448Q38211598-AFD7A795-29EE-4D8D-BACB-DD582160F308Q38492153-2E10DB28-9694-467E-99B0-5CC514E0C644Q38632634-CE407966-BBAA-4BD9-AFD9-E39214D7C6A6Q38721782-AAAF2ED4-F6F9-469C-A3A0-C7D64C9BDC64Q38897744-A620F225-917D-463A-BD06-654CDD26657FQ38964075-7838043B-C492-4C38-852A-1CA37D5C7FF5Q39027066-9DF300DD-DE36-4AC2-9F07-779AE1CFA207Q41128751-3A974769-5334-43D3-9884-202CDBA7849FQ42412981-1ED460C6-C761-48C2-AF35-02968E57C0BCQ42675375-8BE432F6-D9B6-4FA0-857C-48FD68733395Q45997277-D2050742-9476-49B1-AC4F-55C1681AD4B6Q47345427-72FDDE0F-D3AF-473D-8D7D-CA737B798971Q48259049-00C873EC-24FF-45C6-865F-3B0CE7FD9F92Q55434033-8882E7CA-DAA1-4155-A949-D88D980F8529
P2860
Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Combined inhibition of EGFR an ...... d the killing of cancer cells.
@en
Combined inhibition of EGFR an ...... d the killing of cancer cells.
@nl
type
label
Combined inhibition of EGFR an ...... d the killing of cancer cells.
@en
Combined inhibition of EGFR an ...... d the killing of cancer cells.
@nl
prefLabel
Combined inhibition of EGFR an ...... d the killing of cancer cells.
@en
Combined inhibition of EGFR an ...... d the killing of cancer cells.
@nl
P2093
P1433
P1476
Combined inhibition of EGFR an ...... d the killing of cancer cells.
@en
P2093
Adam Siddiqui-Jain
Caroline Ho
Chris Proffitt
Daniel Bunag
David M Ryckman
Denis Drygin
John K C Lim
Joshua Bliesath
Kenna Anderes
Mayuko Omori
P304
P356
10.1016/J.CANLET.2012.02.032
P407
P577
2012-03-02T00:00:00Z